Express News | Regeneron Shares Fall 1% After Lower Than Expected Sales of High Dose Version of Co's Eye Drug Eylea
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,150
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,182
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Regeneron Beats in Q2 as Eylea Tops Expectations
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
Regeneron Pharmaceuticals | 10-Q: Quarterly report
Stock Futures Rise Ahead of Apple, Amazon Earnings; Asia Churns, Europe Down
Regeneron Pharmaceuticals Q2 Adjusted Earnings, Revenue Increase
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Posts Q2 Revenue $3.55B, Vs. Street Est of $3.39B
Express News | Regeneron Outlook FY Capex USD 750-820 Million
Express News | Regeneron Q2 Adjusted EPS USD 11.56 Vs. IBES Estimate USD 10.6
Express News | Regeneron Q2 EPS USD 12.41
Express News | Regeneron Q2 Revenue USD 3,550 Million Vs. IBES Estimate USD 3,379 Million
Express News | Regeneron Reports Second Quarter 2024 Financial and Operating Results
Regeneron Pharma 2Q EPS $12.41 >REGN
Meta, Arm, Qualcomm, Carvana, Teladoc, Apple, Amazon, and More Stock Market Movers
Regeneron Pharmaceuticals Q2 2024 Earnings Preview
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?